Clincosm LogoSign in Get a demo

The Etiology of New-onset Status Epilepticus

Sponsor
Jie Liu (Other)
Overall Status
Completed
CT.gov ID
NCT05647525
Collaborator
(none)
60
Enrollment
1
Location
20.9
Actual Duration (Months)
2.9
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study will help to identify the causes of new epilepsy and provide a basis for the development of a rational and standardized diagnosis and treatment plan to reduce the rate of disability and death.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Perform autoimmune encephalitis titer tests

Study Design

Study Type:
Observational [Patient Registry]
Actual Enrollment :
60 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Sichuan Academy of Medical Sciences - Sichuan Provincial People's Hospital
Actual Study Start Date :
Jan 1, 2021
Actual Primary Completion Date :
Aug 30, 2022
Actual Study Completion Date :
Sep 30, 2022

Arms and Interventions

Arm Intervention/Treatment
status epilepticus with autoimmune encephalitis; status epilepticus without autoimmune encephalitis

To study the relationship between autoimmune-related antibody titres and prognosis during the six-month follow-up

Diagnostic Test: Perform autoimmune encephalitis titer tests
We only follow up without intervention.
Other Names:
  • We only follow up without intervention.

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Death [2021-12--2022-12]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Inclusion Criteria:

    • Clinical diagnosis of Status Epilepticus

    • Sign the informed consent form

    Exclusion Criteria:

    • Patients with previous epilepsy

    • Missing information such as basic information and treatment history

    • Long-term smoking, alcohol and drug abuse

    • Pregnant and breastfeeding women

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Jie Liu Chengdu Sichuan China

    Sponsors and Collaborators

    • Jie Liu

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Jie Liu, Professor, Sichuan Provincial People's Hospital
    ClinicalTrials.gov Identifier:
    NCT05647525
    Other Study ID Numbers:
    • Liujiessy
    First Posted:
    Dec 12, 2022
    Last Update Posted:
    Dec 15, 2022
    Last Verified:
    Dec 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Status Epilepticus

    Study Results

    No Results Posted as of Dec 15, 2022